Welcome to our dedicated page for Seres Therapeutics news (Ticker: MCRB), a resource for investors and traders seeking the latest updates and insights on Seres Therapeutics stock.
Seres Therapeutics Inc (Nasdaq: MCRB) is a clinical-stage biotechnology leader developing microbiome therapies to treat dysbiosis-related conditions. This page provides investors and medical professionals with essential updates on FDA milestones, clinical trial progress, and strategic collaborations shaping the future of ecobiotic treatments.
Access authoritative reports on regulatory approvals, research breakthroughs, and financial developments in one centralized hub. Our curated news collection includes updates on VOWST commercialization, pipeline candidates like SER-155, and partnerships advancing microbiome science.
Key coverage areas include clinical trial results, manufacturing innovations, and peer-reviewed research insights. All content is verified through primary sources to ensure accuracy for investment analysis and medical decision-making.
Bookmark this page for real-time updates on Seres Therapeutics' progress in redefining microbiome-based healthcare solutions. Check back regularly for objective reporting on developments impacting both patient care and long-term corporate strategy.
Seres Therapeutics announced three poster presentations at the upcoming 2025 Digestive Disease Week (DDW) Conference in San Diego. The company will showcase new research on live biotherapeutics for treating inflammatory and immune diseases, including ulcerative colitis and Crohn's disease.
The presentations include two new research posters focusing on:
- Characterization of IBD microbiomes to evaluate candidate biomarkers
- Biomarkers of microbiome disruption for patient selection in UC trials
A third poster will present previously disclosed results from the SER-155 Phase 1b study, which demonstrated positive outcomes in promoting intestinal barrier integrity and modulating inflammatory responses. Seres is actively seeking partnerships to advance their biotherapeutics development in inflammatory and immune diseases.
Seres Therapeutics (Nasdaq: MCRB), a leading live biotherapeutics company, has scheduled a conference call and live audio webcast for May 7, 2025, at 8:30 a.m. ET to discuss their first quarter 2025 financial results and provide business updates.
Investors can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) with conference ID 4618787. The webcast will be available in the 'Investors and News' section of the Seres website and will remain archived for approximately 21 days after the event.
Seres Therapeutics (MCRB) reported its Q4 and full year 2024 financial results, highlighting significant progress with SER-155, their live biotherapeutic candidate for preventing bloodstream infections in allogeneic hematopoietic stem cell transplant recipients.
Key developments include:
- SER-155 showed a 77% relative risk reduction in bloodstream infections in Phase 1b study
- FDA granted Breakthrough Therapy designation in December 2024
- Company plans to submit draft protocol for next study to FDA in Q2 2025
- Recent FDA feedback supports bloodstream infection reduction at day 30 post-HSCT as primary endpoint
Financial highlights: Net loss from continuing operations was $125.8M for 2024, compared to $190.1M in 2023. Cash position of $30.8M as of December 31, 2024, with expected funding into Q1 2026, including anticipated Nestlé payments.
Seres Therapeutics (MCRB) has scheduled a conference call and live audio webcast for March 13, 2025, at 8:30 a.m. ET to discuss their fourth quarter and full year 2024 financial results along with business updates. Interested participants can access the conference call by dialing 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 6331602. The webcast will be available in the Investors and News section of the Seres website, with a replay accessible approximately two hours after the event and archived for about 21 days.
Seres Therapeutics (MCRB) has received FDA feedback on its SER-155 development strategy for allogeneic hematopoietic stem cell transplant (allo-HSCT) patients. The FDA supported using reduction in bloodstream infections at 30 days post-HSCT as the primary endpoint for the next study, recommending it be a Phase 2 trial.
The company is considering either a Phase 2 or a Phase 2/3 design for operational efficiency and plans to submit the protocol to FDA in Q2 2024. The upcoming study will build on the successful Phase 1b Cohort 2 trial, which demonstrated a 77% relative risk reduction in bloodstream infections, reduced systemic antibiotic exposure, and lower febrile neutropenia incidence.
Seres is actively seeking a development partner for SER-155 in allo-HSCT and awaits additional FDA feedback on submitted clarification questions.
Seres Therapeutics (MCRB) has received a $50 million installment payment from Nestlé Health Science, related to the previously announced sale of its VOWST business. This payment was received as planned, with Seres meeting its transition obligations. The company anticipates an additional $25 million installment payment (less approximately $1.5M in employment-related payments) from Nestlé Health Science in July 2025. Based on current cash position, including these payments and considering transaction-related obligations and operating plans, Seres expects to maintain operational funding into the first quarter of 2026.
Seres Therapeutics (MCRB) announced new biomarker results from its SER-155 Phase 1b study in allogenic stem cell transplantation patients. The data showed statistically significant improvements in epithelial barrier integrity and decreased systemic inflammatory biomarkers compared to placebo, supporting the previously reported 77% reduction in bloodstream infections.
The company received FDA Breakthrough Therapy designation for SER-155 in December 2024 and expects agency feedback on its next registrational study this quarter. Market research with healthcare professionals and payers confirmed high unmet need and strong value proposition for SER-155 in preventing bloodstream infections.
Financially, Seres had approximately $31 million in cash as of December 31, 2024, and expects to receive about $75 million in installment payments from Nestlé Health Science in 2025. The company projects its cash runway to extend into Q1 2026 and is actively seeking partnerships to advance SER-155 development.
Seres Therapeutics (MCRB) announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, where CEO Eric Shaff will present on January 16, 2025. The presentation will focus on the company's biotherapeutics pipeline, particularly SER-155, which recently received FDA Breakthrough Therapy designation for reducing bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant.
The Phase 1b study results showed SER-155 achieved a 77% relative risk reduction in bloodstream infections, significant reduction in antibiotic exposure, and lower febrile neutropenia incidence. Seres is actively seeking partners to explore SER-155's development for additional vulnerable populations, including autologous-HSCT patients, cancer patients, CAR-T recipients, and others.
Seres Therapeutics (MCRB) announced FDA Breakthrough Therapy designation for SER-155, targeting bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant. Phase 1b clinical data showed a 77% relative risk reduction in bacterial bloodstream infections versus placebo, with significantly reduced antibiotic exposure (9.2 vs 21.1 days).
The treatment demonstrated positive safety profile with no treatment-related serious adverse events. A Breakthrough Therapy meeting with FDA is expected in Q1 2025. The company is seeking strategic partnerships to accelerate development and expand to multiple target populations beyond the current ~40,000 worldwide allo-HSCT patients.
Seres Therapeutics (Nasdaq: MCRB) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. President and CEO Eric Shaff will engage in a fireside chat on December 3, 2024, at 4:30 p.m. ET. The event will be accessible via live webcast through the company's website under the 'Events and Presentations' tab in the 'Investors and News' section, with replay available after the event.
FAQ
What is the current stock price of Seres Therapeutics (MCRB)?
What is the market cap of Seres Therapeutics (MCRB)?
